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Fig. 2. Roentgenogram of the chest 30 days after repair. 
A residual hematoma of the right upper lobe and good 
expansion of the right lower lobe can be seen. 
HLA ANTIBODIES SPECIFIC FOR CRYOPRESERVED HEART VALVE "HOMOGRAFTS" IN 
CHILDREN 
Inez den Hamer, MD, a Bouke Hepkema, PhD, b Jochum Prop, MD, ~ Nynke Elzenga, MD, c and Tjark Ebels, MD, a 
Groningen, The Netherlands 
For more than 30 years, human heart valves have been 
used as grafts for replacement of diseased aortic and 
pulmonary valves. These heart valve allografts, tradition- 
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ally referred to as "homografts," were long assumed to be 
immunologicaily inert and were supposed not to be af- 
fected by rejection, in contrast to organ transplants. 
However, in children, degeneration f the heart valve a!lo- 
grafts is frequently observed. 1 Findings in clinical 2'3 and 
experimental 4 studies uggested that this degeneration might 
be caused by an immune response. Recently, Smith and 
colleagues 5 from the Harefield Hospital, United Kingdom , 
found donor HLA-specific antibodies inadults after implan- 
tation of fresh or antibiotic-sterilized aortic valve a!lografts. 
This demonstrated that human heart valve allografts can 
induce immune responses in patients. 
Most  cardiac centers do not have fresh heart valve 
allografts available and use cryopreserved valves instead, 
which have been shown to become less immunogenic 
during the cryopreservatiOn procedure. 3 Therefore we 
investigated whether cryopreserved heart valve allografts 
induced donor-specific HLA antibodies in children. 
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Table I. Specificity and isotype of HIM antibodies in eight children with cryopreserved heart valve allografls 
Type of valve HLA antigens of HLA antibodies Red blood 
Serum sample* Age? Diagnosis allografl valve donor and isotype cells~ 
2 Wk 1 Pulmonary valve atresia Pulmonary Not determined B17; IgM 4 
5 Mo 1 Pulmonary valve atresia Aortic A1, A2, B18, B37 A1; IgG 11 
1 Yr 11 Tetralogy of Fallot Aortic Not determined No 3 
3 Yr 0 Truncus arteriosus Aortic First: A1, A2, B37, B39 No 0 
3.5 Yr§ Second: A2, A24, B18, B35 
4 Yr 17 Pulmonary valve stenosis Pulmonary A24, A32(A19), B44, B61 A10, A19; IgG 14 
4.5 Yr 4 Pulmonary valve insufficiency Aortic Not determined No 5 
5 Yr 1 Tetralogy of Fallot Aortic A24, B51(B5), B49 B5, B49; IgG 8 
5 Yr 6 Aortic valve stenosis Aortic First: A1, A24, B8, B39 No 3 
6 Yr§ Second: Not determined 
*Time after operation. 
?Age in years at time of operation. 
:~Units of unfiltered red blood cell concentrates r ceived perioperatively. 
§Patient underwent operation twice. 
Table II. Specificity of HLA antibodies in one 
patient and HIM antigens of heart valve donor and 
blood donors 
HLA specificity~antigens 
HLA antibodies B5, B49 
Valve donor A24, B51(B5), B49 
Blood donor 1 A2, B7, B62 
Blood donor 2 A2, A3, B7 
Blood donor 3 A29, A32, B44 
Blood donor 4 A1, A2, B62, B37 
Blood donor 5 A2, A30/A31, B44, B27 
Blood donor 6 A1, A24, B7, B8 
Blood donor 7 A3, A30/31, B13, B35 
Blood donor 8 Not determined 
Eight children who underwent operation for congenital 
heart defects (Table I) were studied between 2weeks and 
5 years after implantation of a cryopreserved heart valve 
allograft. The age of the children at the time of operation 
ranged from 1 month to 17 years; two of the children had 
undergone operation twice; all but one of the children 
received unfiltered red blood cell concentrates (Table I). 
In a study protocol approved by the Medical Ethical 
Committee of our institution, the patients (and parents) 
allowed collection of a single blood sample for analysis of 
HLA antibodies; no permission was obtained for HLA 
typing in these patients. 
For the detection of cytotoxic anti-HLA class I antibod- 
ies and for the crossmatches, the standard National Insti- 
tutes of Health microlymphocytotoxicity technique and a 
more sensitive assay that used longer incubation times 
were used. The sera were screened against peripheral 
blood lymphocytes of a panel of 40 different HLA-typed 
healthy volunteers. Pretreatment of the sera with dithio- 
threitol was used to differentiate between immunoglobu- 
lin (Ig) G and IgM antibodies. 
Cytotoxic HLA antibodies were detected in the serum 
of four of the eight children. In three children HLA 
antibodies of the IgG isotype were directed specifically 
against HLA antigens of the allograff donor; the donor 
specificity of the IgM HLA antibodies detected in the 
fourth patient could not be confirmed because the donor 
HLA typing was not available. 
In one patient, with HLA antibodies pecific for the 
relatively rare HLA-B5 and -B49 antigens, analysis was 
done in detai l, to exclude the possibility that the HLA 
antibodies were induced by blood transfusions. All but 
one of the blood donors were retrospectively t ped for 
HLA antigens. None of the blood donors had the B5 or 
B49 antigens (Table II) and the crossmatches between the 
serum of the patient and lymphocytes of the blood donors 
were all negative. One blood donor was not available for 
HLA typing but it is unlikely that this single donor had 
HLA antigens corresponding with the specificities of the 
HLA antibodies. 
This report demonstrates that in children cryopreserved 
heart valve allografts can induce donor-specific, ytotoxic 
HLA antibody responses. Children have high humoral 
anti-HLA responsiveness, 6 and they also frequently show 
degeneration of implanted heart valve allograft) If we 
accept the concept that this degeneration is immune 
mediated, the obvious consequence for clinical treatment 
of the children would be to prevent he immune response 
against he heart valve allograft. One way to achieve this 
could be treatment of patients with immunosuppressive 
drugs as was shown effective in rats. 7 For children this 
treatment is not appealing, because of the side effects of 
immunosuppression. 
Another way to prevent immune responses against 
valve allografts is prospective selection of an HLA- 
matched valve for each patient. Ideally the allografts 
should be matched for both HLA class I and II antigens. 
Class I matching has been shown to reduce rejection in 
high-risk corneal transplantation 8 and class II matching 
reduced in vitro the stimulation of lymphocytes by heart 
valve tissue. 3 The major obstacle to achieving adequate 
HLA matching of heart valve allografts, next to size 
matching, is that it would restrict the availability of 
suitable valve allografts for individual patients. In addi- 
tion, the effect of prospective matching would only be of 
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benefit for patients with an increased risk for degenera- 
tion of the valves. At present it is impossible to assess 
prospectively which patients are at risk for immune- 
mediated valve degeneration. However, children listed for 
retransplantation for reasons other than technical failure 
and children with preformed HLA antibodies are likely 
candidates. We recommend that for these patients at 
"high risk" a crossmatch-negative, HLA-matched heart 
valve allograft be selected. 
The cooperation of the Stichting Rode Kruis Bloed- 
bank Noord Nederland, their blood donors, and Bio 
Implant Services for providing the HLA types of the 
donors is gratefully acknowledged. 
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MULTIPLE EPISODES OF THROMBOSIS WITH BIVENTRICULAR SUPPORT DEVICES WITH 
INADEQUATE ANTICOAGULATION AND EVIDENCE OF ACCELERATED INTRAVASCULAR 
COAGULATION 
George J. Despotis, MD, Vladimir Levine, MD, PhD, Heinrich Joist, MD, PhD, Samuel A. Santoro, MD, PhD, and 
Eric Mendeloff, MD, St. Louis, Mo. 
Ventricular assist devices (VADs) may induce com- 
plex hemostatic abnormalities mediated by excessive 
activation of platelets, coagulation, and fibrinolysis with 
resulting consumption of platelets and labile coagula- 
tion factors and sometimes associated with thrombo- 
sis. 1-3 We describe the case of a teenaged boy with 
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dilated cardiomyopathy whose course was initially com- 
plicated by excessive bleeding. He subsequently had 
multiple episodes of thrombosis of biventricular assist 
devices (BVADs) that were associated with accelerated 
intravascular coagulation temporally related to subop- 
timal warfarin anticoagulation. 
A 15-year-old boy with Becker's muscular dystrophy 
was admitted for treatment of progressive congestive 
heart failure. Transthoracic echocardiography revealed 
dilated cardiomyopathy with severely reduced ejection 
fraction and a right ventricular mural thrombus. Over a 
3-week period after admission, he began having increas- 
ingly severe symptoms of congestive heart failure with 
respiratory distress and profound hypotension. The symp- 
toms were unresponsive to aggressive medical manage- 
ment with inotropic support, diuresis, afterload reduction, 
and intraaortic balloon counterpulsation. After the devel- 
opment of cardiogenic shock, ABIOMED BVADs 
(ABIOMED Cardiovascular, Inc., Danvers, Mass.) were 
implanted as a bridge to transplantation (day 1). The 
patient was given a continuous infusion of heparin at a 
rate of 1500 to 2200 U/hr to maintain the celite activated 
clotting time between 180 and 200 seconds. While he was 
